Global MarketsOctober 1 at 03:32 AM

Zealand Pharma (ZEAL DC) announces positive results from the Phase 3 SYNCHRONIZE-2 trial, with survodutide achieves up to 13.1% weight loss alongside significant improvements in glycemic control in people with obesity and type 2 diabetes

StockNow breaking-news AI analysis

The 2026-10-01 headline reports up to 13.1% weight loss and significant glycemic-control improvements in SYNCHRONIZE-2; detailed outcomes and safety data are unavailable.

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Commodities

The US has reportedly told France and Germany to release emergency diesel stocks or face a possible export ban, according to sources

Politics

[MARKET UPDATE] Energy benchmarks continue to climb (Brent +1.1%), lifting bond yields (UK 30yr 6%) and weighing on the equity space; European tech sector now flat after opening +0.5%; fresh newsflow light